天賜材料(002709.SZ):擬投建捷克年產10萬噸鋰電池電解液項目(一期)
格隆匯 8 月 18日丨天賜材料(002709.SZ)公佈,公司於2020年8月17日召開了第五屆董事會第四次會議、第五屆監事會第三會議,審議通過了《關於投資建設捷克年產10萬噸鋰電池電解液項目(一期)的議案》,同意公司全資子公司天賜材料捷克有限公司(英文名稱:Tinci Materials Technology Czech S.R.O.)投資建設捷克年產10萬噸鋰電池電解液項目(一期),項目總投資為人民幣2.75億元,其中建設投資為1.95億元,鋪底流動資金為8000萬元。該議案尚需提交公司股東大會表決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.